SCHEMBL23535740

SCHEMBL23535740

O=C(O)c1ccc(-c2cnn(C3CCCCO3)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.47
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RXRG P48443 1/20 0.45
KDM5B Q9UGL1 1/20 0.42
FGFR1 P11362 2/20 0.41
DDR2 Q16832 1/20 0.41
CD274 Q9NZQ7 1/20 0.40
JAK2 O60674 2/20 0.40
CHEK1 O14757 1/20 0.39
FASN P49327 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
MAP4K4 O95819 1/20 0.38
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041685 0.89 MKNK1 (0.46) MCL1RXRARXRBRXRGKDM5B
SCHEMBL5139638 0.87 ACHE (0.43) MCL1RXRARXRBRXRGKDM5B
Fluoride SCHEMBL14796503 0.87 ACHE (0.43) MCL1RXRARXRBRXRGKDM5B
SCHEMBL28375403 0.86 MCL1 (0.45) MCL1RXRARXRBRXRGKDM5B
SCHEMBL23535723 0.86 MCL1 (0.45) MCL1RXRARXRBRXRGKDM5B
SCHEMBL28481979 0.85 MCL1 (0.46) MCL1RXRARXRBRXRGKDM5B
SCHEMBL30867591 0.84 MCL1 (0.43) MCL1RXRARXRBRXRGKDM5B
SCHEMBL28483450 0.84 MCL1 (0.49) MCL1RXRARXRBRXRGKDM5B
SCHEMBL29194155 0.83 RXRA (0.47) MCL1RXRARXRBRXRGFGFR1
SCHEMBL28962279 0.82 RXRA (0.43) MCL1RXRARXRBRXRGCD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078121-A1 INHIBITORS OF ENL/AF9 YEATS AND FLT3 BRIDGE MEDICINES (US) 2026-03-19 US disclosed
CN-115427035-B ENL/AF9 YEATS inhibitors 洛克菲勒大学 2025-04-22 CN disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 US disclosed
CN-115427035-A ENL/AF9YEATS inhibitors 洛克菲勒大学 2022-12-02 CN disclosed
EP-4076440-A1 INHIBITORS OF ENL/AF9 YEATS The Rockefeller University (US) 2022-10-26 EP disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed
WO-2021127166-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 MCL1 29/4885RXRA 3032/4885RXRB 3221/4885
US-20260078121-A1 INHIBITORS OF ENL/AF9 YEATS AND FLT3 MLLT3, MLLT1, FLT3 MCL1 5/4885RXRA 2096/4885RXRB 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.